Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 5/20 | 0.47 |
| ▸ | MMP3 | P08254 | 5/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GPR139 | Q6DWJ6 | 7/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7224204 | 0.79 | MMP2 (0.45) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL7232020 | 0.79 | MMP2 (0.63) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL4216415 | 0.73 | GPR139 (0.57) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL1841540 | 0.73 | GPR139 (0.57) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL379512 | 0.73 | GPR139 (0.57) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL18787411 | 0.73 | KMT2A (0.67) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL379424 | 0.70 | GPR139 (0.51) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL1843935 | 0.70 | GPR139 (0.51) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL5514590 | 0.70 | GPR139 (0.51) | MMP2MMP3MMP9MMP13MMP1 | |
| SCHEMBL379712 | 0.70 | GPR139 (0.53) | MMP2MMP3MMP9MMP13MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6605604-B1 | Tumour necrosis factor alpha release inhibitors; efficiency treatment of cancers, rheumatic diseases, arthritis, ulcers, atherosclerosis, asthma | LES LABORATOIRES SERVIER (FR) | 2003-08-12 | — | — | US | disclosed |